Study of Aripiprazole in Patients With a History of Bipolar Disorder

This study has been completed.
Sponsor:
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00036348
First received: May 8, 2002
Last updated: November 7, 2013
Last verified: September 2007
  Purpose

The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with a history of bipolar disorder.


Condition Intervention Phase
Bipolar Disorder
Drug: Aripiprazole
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Study Start Date: March 2000
Study Completion Date: June 2003
Primary Completion Date: June 2003 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Patients with a history of Bipolar I Disorder

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00036348

Locations
United States, Alabama
Local Institution
Birmingham, Alabama, United States
Local Institution
Tuscaloosa, Alabama, United States
United States, California
Local Institution
Chillicothe, California, United States
Local Institution
Riverside, California, United States
Local Institution
Stanford, California, United States
Local Institution
Torrance, California, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
United States, Illinois
Local Institution
Chicago, Illinois, United States
United States, Kentucky
Local Institution
Louisville, Kentucky, United States
United States, Louisiana
Local Institution
Shreveport, Louisiana, United States
United States, Massachusetts
Local Institution
Belmont, Massachusetts, United States
United States, Nevada
Local Institution
Las Vegas, Nevada, United States
United States, New Mexico
Local Institution
Albuquerque, New Mexico, United States
United States, New York
Local Institution
New York, New York, United States
United States, Pennsylvania
Local Institution
Philadelphia, Pennsylvania, United States
United States, Tennessee
Local Institution
Memphis, Tennessee, United States
Local Institution
Nashville, Tennessee, United States
United States, Texas
Local Institution
Austin, Texas, United States
Local Institution
San Antonio, Texas, United States
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
  More Information

Additional Information:
No publications provided by Otsuka Pharmaceutical Development & Commercialization, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00036348     History of Changes
Other Study ID Numbers: CN138-010
Study First Received: May 8, 2002
Last Updated: November 7, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Bipolar I disorder

Additional relevant MeSH terms:
Disease
Bipolar Disorder
Pathologic Processes
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Aripiprazole
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on September 18, 2014